REPORT ID 3353

United States Prophylactic Human Vaccine Market Report 2017

Publish Date
13-Dec-17
Pages
101
Format
Electronic (PDF)

In this report, the United States Prophylactic Human Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Prophylactic Human Vaccine in these regions, from 2012 to 2022 (forecast).

United States Prophylactic Human Vaccine market competition by top manufacturers/players, with Prophylactic Human Vaccine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    GSK
    Biovac
    McKesson Medical
    Merck
    Merial
    Zoetis
    Sanofi
    ...

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Inactivated Vaccine
    Attenuated Vaccine
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Scientific Research
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Prophylactic Human Vaccine Market Report 2017
1 Prophylactic Human Vaccine Overview
    1.1 Product Overview and Scope of Prophylactic Human Vaccine
    1.2 Classification of Prophylactic Human Vaccine by Product Category
        1.2.1 United States Prophylactic Human Vaccine Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Prophylactic Human Vaccine Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Inactivated Vaccine
        1.2.4 Attenuated Vaccine
        1.2.5 Others
    1.3 United States Prophylactic Human Vaccine Market by Application/End Users
        1.3.1 United States Prophylactic Human Vaccine Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hospital
        1.3.3 Scientific Research
        1.3.4 Others
    1.4 United States Prophylactic Human Vaccine Market by Region
        1.4.1 United States Prophylactic Human Vaccine Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Prophylactic Human Vaccine Status and Prospect (2012-2022)
        1.4.3 Southwest Prophylactic Human Vaccine Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Prophylactic Human Vaccine Status and Prospect (2012-2022)
        1.4.5 New England Prophylactic Human Vaccine Status and Prospect (2012-2022)
        1.4.6 The South Prophylactic Human Vaccine Status and Prospect (2012-2022)
        1.4.7 The Midwest Prophylactic Human Vaccine Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Prophylactic Human Vaccine (2012-2022)
        1.5.1 United States Prophylactic Human Vaccine Sales and Growth Rate (2012-2022)
        1.5.2 United States Prophylactic Human Vaccine Revenue and Growth Rate (2012-2022)

2 United States Prophylactic Human Vaccine Market Competition by Players/Suppliers
    2.1 United States Prophylactic Human Vaccine Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Prophylactic Human Vaccine Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Prophylactic Human Vaccine Average Price by Players/Suppliers (2012-2017)
    2.4 United States Prophylactic Human Vaccine Market Competitive Situation and Trends
        2.4.1 United States Prophylactic Human Vaccine Market Concentration Rate
        2.4.2 United States Prophylactic Human Vaccine Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Prophylactic Human Vaccine Manufacturing Base Distribution, Sales Area, Product Type

3 United States Prophylactic Human Vaccine Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Prophylactic Human Vaccine Sales and Market Share by Region (2012-2017)
    3.2 United States Prophylactic Human Vaccine Revenue and Market Share by Region (2012-2017)
    3.3 United States Prophylactic Human Vaccine Price by Region (2012-2017)

4 United States Prophylactic Human Vaccine Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Prophylactic Human Vaccine Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Prophylactic Human Vaccine Revenue and Market Share by Type (2012-2017)
    4.3 United States Prophylactic Human Vaccine Price by Type (2012-2017)
    4.4 United States Prophylactic Human Vaccine Sales Growth Rate by Type (2012-2017)

5 United States Prophylactic Human Vaccine Sales (Volume) by Application (2012-2017)
    5.1 United States Prophylactic Human Vaccine Sales and Market Share by Application (2012-2017)
    5.2 United States Prophylactic Human Vaccine Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Prophylactic Human Vaccine Players/Suppliers Profiles and Sales Data
    6.1 GSK
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Prophylactic Human Vaccine Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 GSK Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Biovac
        6.2.2 Prophylactic Human Vaccine Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Biovac Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 McKesson Medical
        6.3.2 Prophylactic Human Vaccine Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 McKesson Medical Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Merck
        6.4.2 Prophylactic Human Vaccine Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Merck Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Merial
        6.5.2 Prophylactic Human Vaccine Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Merial Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Zoetis
        6.6.2 Prophylactic Human Vaccine Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Zoetis Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Sanofi
        6.7.2 Prophylactic Human Vaccine Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Sanofi Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    ...

7 Prophylactic Human Vaccine Manufacturing Cost Analysis
    7.1 Prophylactic Human Vaccine Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Prophylactic Human Vaccine

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Prophylactic Human Vaccine Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Prophylactic Human Vaccine Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Prophylactic Human Vaccine Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Prophylactic Human Vaccine Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Prophylactic Human Vaccine Sales Volume Forecast by Type (2017-2022)
    11.3 United States Prophylactic Human Vaccine Sales Volume Forecast by Application (2017-2022)
    11.4 United States Prophylactic Human Vaccine Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer